Skip to main content

Advertisement

SpringerLink
Log in

Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

In a double-blind, placebo controlled study, ipriflavone (600 mg/day, T.D.D.) or identical placebo tablets were given with 500 mg/day of calcium to patients treated with the gonadotropin hormone-releasing hormone agonist (Gn-RH-A) leuproreline acetate, 3.75 mg every 30 days for 6 months. In placebo-treated subjects (n = 39), urinary hydroxyproline excretion and plasma osteocalcin levels snowed a significant (P < 0.01 and P < 0.05, respectively) increase, whereas spine bone density and total body bone density significantly (P < 0.001 and P < 0.05, respectively) decreased after 3 and 6 months of GnRH-A administration. Conversely, in the ipriflavone-treated group (n = 39), no significant difference in bone markers and bone density was evidenced. These data indicate that ipriflavone can restrain the bone remodeling processes and prevent the rapid bone loss that follows medically induced hypogonadism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Devogelaer JP, De Deuxchaisnes CN, Donnez J, Thomas K (1987) LHRH analogues and bone loss. Lancet 1498–1501

  2. Matta WH, Shaw RW, Hesp R, Katz D (1987) Hypogonadism induced by luteinising hormone-releasing hormone agonist analogues: effects on bone density in premenopausal women. Br Med J 294:1523–1524

    Article  CAS  Google Scholar 

  3. Matta WH, Shaw RW, Hesp R, Evans R (1988) Reversible trabecular bone density loss following induced hypoestrogenism with GnRH analogue buserelin in premenopausal women. Clin Endocrinol 29:45–51

    Article  CAS  Google Scholar 

  4. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C (1988) The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 67:701–706

    PubMed  CAS  Google Scholar 

  5. Dawood MY, Lewis V, Ramos J (1989) Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 52:21–26

    PubMed  CAS  Google Scholar 

  6. Jacobson JB (1990) Effects of nafarelin on bone density. Am J Obstet Gynecol 162:591–592

    PubMed  CAS  Google Scholar 

  7. Schalli AR, Jestila KJ, Simon JA (1993) Leuprolide acetate and bone mineral density measured by quantitative digitized radiography. Fertil Steril 59:674–676

    Google Scholar 

  8. Riis BJ, Christiansen C, Johansen JS, Jacobson J (1990) Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 70:920–924

    Article  PubMed  CAS  Google Scholar 

  9. Surrey ES, Judd HL (1992) Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 75:558–563

    Article  PubMed  CAS  Google Scholar 

  10. Judd HL (1992) Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy. Am J Obstet Gynecol 166:752–756

    PubMed  CAS  Google Scholar 

  11. West CP, Lumsden MA, Hillier H, Sweeting V, Baird DT (1992) Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical treatment of uterine fibroids. Hum Reprod 7:328–332

    PubMed  CAS  Google Scholar 

  12. Leather AT, Studd JWW, Watson NR, Holland EFN (1987) The prevention of bone loss in young women treated with GnRH analogues with “add-back” estrogen therapy. Obstet Gynecol 81:104–107

    Google Scholar 

  13. Suda A (1987) Effect of parathyroid hormone on parietal bones of rats, and effect of ipriflavone. J Bone Miner Met 5:51–56

    Google Scholar 

  14. Bonucci E, Ballanti P, Martelli A, Mereto E, Brambilla G, Bianco P, Bufalino L (1992) Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats. Calcif Tissue Int 50:314–319

    Article  PubMed  CAS  Google Scholar 

  15. Notoya K, Yoshida K, Taketomi S, Yamazaki I, Kumegawa M (1992) Inhibitory effect of ipriflavone on pit formation in mouse unfractionated bone cells. Calcif Tissue Int 51(suppl I):s3-s6

    Article  PubMed  CAS  Google Scholar 

  16. Morita I, Sakaguchi K, Kurachi T, Murota SI (1992) Ipriflavone inhibits murine osteoclast formation in vitro. Calcif Tissue Int 51(suppl 1):s7-s10

    Article  PubMed  CAS  Google Scholar 

  17. Ozawa H, Nakamura H, Me K, Irie M (1992) Histochemical and fine structural study of bone of ipriflavone-treated rats. Calcif Tissue Int 51(suppl 1):s21-s26

    Article  PubMed  CAS  Google Scholar 

  18. Tsuda M, Kitazaki T, Itoh T, Fujita T (1986) The effect of ipriflavone (TC-80) on bone resorption in tissue culture. J Bone Miner Res 1:207–212

    PubMed  CAS  Google Scholar 

  19. Benvenuti S, Tanini A, Frediani U, Bianchi S, Masi L, Casano R, Bufalino L, Serio M, Brandi ML (1991) Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res 6:987–996

    Article  PubMed  CAS  Google Scholar 

  20. Kakai Y, Kawase T, Nakano T, Mikuni-Takagaki Y, Saito S (1992) Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells. Calcif Tissue Int 51(suppl 1):s11-s15

    Article  PubMed  CAS  Google Scholar 

  21. Notoya K, Tsukuda R, Yoshida K, Taketomi S (1992) Stimulatory effect of ipriflavone on formation of bone-like tissue in rat bone marrow stromal cell culture. Calcif Tissue Int 51(suppl 1):s16-s20

    Article  PubMed  CAS  Google Scholar 

  22. Shino A, Matsuo T, Tsuda M, Yamazaki I, Tsukuda R, Kitazaki T, Shiota K, Yoshida K (1986) Effect of ipriflavone on bone and mineral metabolism in the streptozotocin diabetic rats. J Bone Miner Met 3:27–37

    Google Scholar 

  23. Yamazaki I, Shino A, Tsukuda R (1986) Effect of ipriflavone on osteoporosis induced by ovariectomy in rats. J Bone Miner Met 3:205–210

    CAS  Google Scholar 

  24. Yamazaki I, Shino A, Shimizu Y, Tsukuda R, Shirakawa Y, Kinoshita M (1986) Effect of ipriflavone on glucocorticoidinduced osteoporosis in rats. Life Sci 38:951–958

    Article  PubMed  CAS  Google Scholar 

  25. Melis GB, Paoletti AM, Cagnacci A, Bufalino L, Spinetti A, Gambacciani M, Fioretti P (1992) Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocrinol Invest 15:755–761

    PubMed  CAS  Google Scholar 

  26. Newman RE, Logan MA (1950) The determination of hydroxyproline. J Biol Chem 184:299–303

    Google Scholar 

  27. Giordani R, Lucchetti A, Nicollini A, Fiochi U (1983) La determinazione dell’idrossiprolina urinaria: confronto fra due metodi. Bollettino della Società Medico-Chirurgica Pisana 4: 1–3

    Google Scholar 

  28. Gambacciani M, Spinetti A, Cappagli B, Taponeco F, Felipetto R, Parrini D, Cappelli N, Fioretti P (1993) Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest 16:333–337

    PubMed  CAS  Google Scholar 

  29. Agnusdei D, Zacchei F, Bigazzi S, Cepollaro C, Nardi P, Montagnani M, Gennari C (1989) Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp Clin Res XV(2):97–104

    Google Scholar 

  30. Agnusdei D, Camporeale A, Zacchei F, Gennari C, Baroni MC, Costi D, Biondi M, Passeri M, Ciacca A, Sbrenna C, Falsettini E, Ventura A (1992) Effects of ipriflavone on bone mass and bone remodeling in patients with established postmenopausal osteoporosis. Curr Ther Res 51:82–91

    Google Scholar 

  31. Passeri M, Biondi M, Costi D, Dall’Aglio E, Pedrazzoni M, Bufalino L, Castiglione GN, Abate G (1995) Effects of 2-year therapy with ipriflavone in elderly women with established osteoporosis. Ital J Mineral Electrolyte Metab 9:137–144

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology “Piero Fioretti”, S. Chiara Hospital, via Roma 67, 56100, Pisa, Italy

    M. Gambacciani, B. Cappagli, L. Piaggesi, M. Ciaponi & A. R. Genazzani

Authors
  1. M. Gambacciani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Cappagli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Piaggesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Ciaponi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. R. Genazzani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gambacciani, M., Cappagli, B., Piaggesi, L. et al. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int 61 (Suppl 1), S15–S18 (1997). https://doi.org/10.1007/s002239900379

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002239900379

Key words

Search

Navigation